Neflamapimod awarded UK Innovation Passport for DLB
CervoMed received Innovation Passport Designation for neflamapimod in dementia with Lewy bodies; additionally, Q2 financial results and updates for both DLB and nonfluent variant primary progressive aphasia programs were provided. The data supports a pivotal Phase 3 strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day